Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
Subscribe To Our Newsletter & Stay Updated
